Fang, Shona
Hedera, Peter http://orcid.org/0000-0003-2699-4085
Borchert, Julia
Schultze, Michael
Weiss, Karl Heinz
Funding for this research was provided by:
Alexion Pharmaceuticals (Alexion Pharmaceuticals)
Article History
Received: 21 March 2024
Accepted: 2 September 2024
First Online: 11 September 2024
Declarations
:
: The observational, retrospective study used anonymized data, which was recorded for reimbursement purposes and is compliant with German data protection regulations. Accordingly, approval of an institutional review board (IRB) or ethics committee was not required.
: Not applicable.
: KHW has no disclosures related to this work. KHW advises for Alexion, Univar, Orphalan, Desitin, Tilomed, Ultragenyx, Pfizer, Vivet therapeutics, Abbvie. SF is an employee of Alexion, AstraZeneca Rare Disease, and may own stock of AstraZeneca. MS was an employee of Kantar Health at the time of the study, which was contracted by Alexion to conduct this study, and he now works for ZEG – Berlin Center for Epidemiology and Health Research GmbH. JB is an employee of WIG2 GmbH, which was contracted by Alexion to conduct this study.